“After listening to families and many other organizations at the center of this community, including the Children’s Oncology Group and Angels for Change, we embarked on an aggressive development path to bring a new recombinant erwinia asparaginase option to market, one that will be manufactured under the highest quality standards and provide a reliable supply to meet the needs of our patients.”